Vitamin K 1 (Phylloquinone)

A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.

Also Known As:

Networked: 348 relevant articles (23 outcomes, 39 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Booth, Sarah L: 11 articles (06/2014 - 08/2003)
2.	Shearer, Martin J: 8 articles (01/2015 - 03/2002)
3.	Cashman, Kevin D: 5 articles (10/2014 - 07/2004)
4.	Vermeer, Cees: 5 articles (08/2014 - 09/2004)
5.	Booth, S L: 4 articles (09/2014 - 12/2001)
6.	Shearer, M J: 4 articles (04/2008 - 06/2002)
7.	Clarke, Paul: 3 articles (01/2015 - 12/2005)
8.	Mitchell, Simon J: 3 articles (01/2015 - 12/2005)
9.	Bulló, Mònica: 3 articles (05/2014 - 11/2012)
10.	Salas-Salvadó, Jordi: 3 articles (05/2014 - 11/2012)

Related Diseases

1.	Vitamin K Deficiency 10/23/1993 - "A single administration of 1 mg vitamin K1 orally or intramuscularly may not afford complete protection against late vitamin K deficiency in healthy breastfed infants. " 08/01/1993 - "In conclusion, weekly administration of vitamin K1 1 mg offers complete protection against vitamin K deficiency and does not result in an accumulation of vitamin K1 in the blood." 12/01/2009 - "The high proportion of false positive results suggest that poor assay specificity at low phylloquinone concentrations is a common problem, which in the clinical setting could lead to underreporting of vitamin K deficiency." 10/23/1993 - "A regimen of 1 mg per week or 25 micrograms vitamin K1 per day proved to be effective in prevention of vitamin K deficiency and the latter is recommended for breastfed infants during the first three months of life." 06/01/2010 - "The method is simple and reliable, allowing accurate vitamin K1 measurement in plasma samples from healthy subjects and patients suffering from vitamin K deficiency."
2.	Hypoprothrombinemias (Prothrombin Deficiency) 01/01/1959 - "Efficacy of water-soluble derivatives of vitamin K1 in counteracting drug-induced hypoprothrombinemia." 11/01/1959 - "[A new study on the therapeutic action of vitamin K1 on hypoprothrombinemia in the premature infant]." 01/01/2010 - "Vitamin K1 is frequently used in the treatment and prevention of hypoprothrombinemia and hemorrhagic disease of the newborn. " 07/01/1963 - "Drug-induced hypoprothrombinemia countered with phytonadione." 07/26/1959 - "[Vitamin K1 and hypoprothrombinemias in hepatic diseases]."
3.	Hemorrhage 12/01/1989 - "Studies of a larger number of patients are necessary before it can be established that maternal antenatal administration of vitamin K1 results in improvement of coagulation and the prevention of intraventricular hemorrhage in premature infants." 08/01/2012 - "Laboratory examinations showed prolonged PT and APTT; bleeding was controlled effectively by administoring vitamin K1 daily. " 12/01/2011 - "For excessive international normalized ratio elevation in the absence of bleeding, low-dose oral vitamin K (1?2.5 mg) is sufficient and achieves the same degree of international normalized ratio correction by 24 h as intravenous therapy. " 07/01/2010 - "Vitamin K1 is an important cofactor for maintaining hemostasis and preventing hemorrhage. " 06/01/2007 - "Initial prothrombin time and activated partial thromboplastin time were both greater than 110 seconds and the patient suffered severe gastric and pulmonary hemorrhage requiring fresh frozen plasma transfusion and parenteral phytonadione administration (up to 100 mg per day). "
4.	Liver Diseases (Liver Disease) 02/01/1995 - "Adverse effects are seen not only in patients with liver-function disturbances but also in patients without liver diseases, and occur mostly after intramuscular or subcutaneous administration of vitamin K1, independent of the total dose. " 03/12/1959 - "[Indications for vitamin K1 in liver disease]." 01/01/1958 - "[Effect of synthetic vitamin K1 in liver diseases in small children]." 02/01/1993 - "Our findings support the observation that liver disease is not a necessary condition for the occurrence of vitamin K1 hypersensitivity." 12/01/2000 - "Oral menadiol appears to be an effective alternative to intravenous phytomenadione in the correction of coagulopathies associated with obstructive liver disease. "
5.	Osteoporosis 02/01/2008 - "Both vitamin K1 and K2 have been shown to exert protective effects against osteoporosis. " 09/01/2006 - "Both vitamin K(1) and K(2) have been shown to exert protective effects against osteoporosis. " 06/01/1985 - "Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis." 08/01/2005 - "Phytonadione and menaquinone may be effective for the prevention and treatment of osteoporosis and arterial calcification." 03/01/2005 - "Vitamin K2 exerts a more powerful influence on bone than vitamin K1, and should be considered for prevention or treatment in those conditions known to contribute to osteoporosis."

Related Drugs and Biologics

1.	Vitamin K 1 (Phylloquinone)
2.	Vitamin K
3.	Vitamin K 2 (Vitamin K2)
4.	cetuximab (Erbitux)
5.	Warfarin (Coumadin)
6.	Blood Coagulation Factors (Coagulation Factor)
7.	Prothrombin (Factor II)
8.	Dicumarol (Dicoumarol)
9.	Vitamin K 3 (Menadione)
10.	Vitamins

Related Therapies and Procedures

1.	Acupuncture Points (Acupuncture Point)
2.	Injections
3.	Intravenous Injections
4.	Subcutaneous Injections
5.	Renal Dialysis (Hemodialysis)